A dasiglucagon dose range of 10 to 70 μg/h was chosen for the trial based on clinical experience from the off-label use of glucagon in CHI patients (9, 14) and supportive data from a pharmacokinetic/pharmacodynamic model developed for a pediatric population (>25 kg) with type 1 diabetes (unpublished). This evidence concerns the gene GCG and type 1 diabetes mellitus.